JRCT ID: jRCT1041240078
Registered date:29/08/2024
SAVANT study
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Hypertension caused by Angiogenesis Inhibitor |
Date of first enrollment | 29/08/2024 |
Target sample size | 40 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | Patient with hypertension due to angiogenesis inhibitor is treated with combination therapy of sacubitril/valsartan200mg and amlodipine5mg. Changes of blood pressure are monitored for 3 weeks (+- 1 week) after the start of treatment. |
Outcome(s)
Primary Outcome | Rate of blood pressure control |
---|---|
Secondary Outcome | Adverse events Change of blood-pressure value |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | (1) Pathologically diagnosed with cancer (2) Diagnosed with drug-induced hypertension caused by angiogenesis inhibitors (3) One calcium antagonist or ARB/ACE inhibitor is used (4) Angiogenesis inhibitor is continued. (5) Creatinine is less than 1.5 mg/dL (6) 18 years or older (7) Written informed consent was obtained |
Exclude criteria | (1)Severe hypertention (CTCAEv5, Grade4) (2)Essential hypertension (Blood pressure 140/90mmHg or more before starting treatment with angiogenesis inhibitors) (3)History of secondary hypertension |
Related Information
Primary Sponsor | Muraoka Nao |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Takuya Oyakawa |
Address | 1007Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka Shizuoka Japan 411-8777 |
Telephone | +81-55-989-5222 |
t.oyakawa@scchr.jp | |
Affiliation | Shizuoka Cancer Center |
Scientific contact | |
Name | Nao Muraoka |
Address | 1007Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka Shizuoka Japan 411-8777 |
Telephone | +81-55-989-5222 |
n.mochizuki@scchr.jp | |
Affiliation | Shizuoka Cancer Center |